Transvaginal permanent mesh probably leads to lower awareness of prolapse (0.5 to 7 years) compared with native tissue repair (moderate certainty).
Transvaginal biological graft showed no clear difference in surgery for recurrent prolapse (1 to 2 years) compared with native tissue repair (moderate certainty).
Transvaginal biological graft showed no clear difference in recurrent prolapse on examination compared with native tissue repair (low certainty).
Transvaginal biological graft showed no clear difference in visceral injury compared with native tissue repair (low certainty).
It is very uncertain whether transvaginal biological graft changes bladder function compared with native tissue repair (very low certainty).
Transvaginal biological graft showed no clear difference in painful intercourse ‐ de novo dyspareunia compared with native tissue repair (moderate certainty).
It is very uncertain whether transvaginal biological graft changes quality of life compared with native tissue repair (very low certainty).
Transvaginal permanent mesh may leads to higher repeat surgery (0.5 to 7 years) compared with native tissue repair (low certainty).
It is very uncertain whether transvaginal permanent mesh changes recurrent prolapse on examination (any compartment) compared with native tissue repair (very low certainty).
Transvaginal permanent mesh may leads to higher visceral injury compared with native tissue repair (low certainty).
Transvaginal permanent mesh probably leads to higher mesh exposure compared with native tissue repair (moderate certainty).
Transvaginal permanent mesh probably leads to higher bladder function compared with native tissue repair (moderate certainty).
Transvaginal permanent mesh showed no clear difference in painful intercourse ‐ de novo dyspareunia compared with native tissue repair (moderate certainty).
It is very uncertain whether transvaginal permanent mesh changes quality of life compared with native tissue repair (very low certainty).
Transvaginal biological graft showed no clear difference in awareness of prolapse (1 to 3 years) compared with native tissue repair (moderate certainty).
It is very uncertain whether summary of findings table ‐ Metformin changes regression of endometrial hyperplasia (with or without atypia) to… compared with megestrol (very low certainty).
It is very uncertain whether summary of findings table ‐ Metformin + megestrol changes progression of endometrial hyperplasia to endometrial cancer compared with megestrol (very low certainty).
It is very uncertain whether summary of findings table ‐ Metformin + megestrol changes hysterectomy rate compared with megestrol (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.